Lonza produces a significant share of the global market of Niacinamide (Vitamin B3) in Guangzhou.
"This project will mark another important milestone in Lonza's long-term strategic plan. It is a key element in achieving the targeted growth for Lonza," said Chief Executive Stefan Borgas in a statement.
In February, Lonza and Singapore's Bio*One Capital said they were together investing $250 million in their new plant in Singapore.